Found 162 articles for: "infliximab"
Importance of Complete Skin Clearance in Psoriasis as a Treatment Goal: Implications for Patient-Reported Outcomes
May 2020 | Volume 19 | Issue 5 | Original Article | 487 | Copyright © May 2020
Psoriasis is associated with physical, psychological, social, and economic burdens that lead to substantial impairment over a patient&rsqu...
Read MorePityriasis Lichenoides Chronica in a Patient With Ankylosing Spondylitis Treated With Etanercept
May 2020 | Volume 19 | Issue 5 | Editorials | 560 | Copyright © May 2020
Background: Pityriasis lichenoides chronica, a papulosquamous disorder often considered a subtype of pityriasis lichenoides. It is considered a clonal T-cell disorder, which may be as...
Read MoreRecapture Rate of Brodalumab in Patients With a Lapse in Treatment
April 2020 | Volume 19 | Issue 4 | Original Article | 384 | Copyright © April 2020
The National Psoriasis Foundation has emphasized the importance of achieving skin clearance targets throughout the course of treatment. However, patients with psoriasis often stop and restart treatmen...
Read MoreThe Effects of Primary Defect Characteristics on Reconstruction Type and Adjunctive Intervention in Mohs Micrographic Surgery: A Retrospective Review
March 2020 | Volume 19 | Issue 3 | Original Article | 264 | Copyright © March 2020
Background: Cosmetic concerns following Mohs Micrographic surgery (MMS) are significant and may require adjunctive treatments for unsatisfactory appearance.
Objective:Read MoreTumor Necrosis Factor Inhibitor-Induced Psoriasis in a Pediatric Crohn’s Disease Patient Successfully Treated with Ustekinumab
March 2020 | Volume 19 | Issue 3 | Case Reports | 328 | Copyright © March 2020
Background: Tumor necrosis factor (TNF) inhibitors are widely used in pediatric patients with inflammatory bowel disease, as well as psoriasis. However, there is growing evidence that...
Read MoreEfficacy and Safety of Systemic Treatments for Skin and Joint Manifestations in Patients With Psoriasis
March 2020 | Volume 19 | Issue 3 | Original Article | 306 | Copyright © March 2020
Psoriasis is a chronic, systemic disease with features suggestive of autoimmune dysregulation. Patients with psoriasis vulgaris frequently experience systemic comorbidities, including cardiovascular a...
Read MoreReal World SB4 (Etanercept Biosimilar) Use in Patients With Psoriasis: Data from the British Association of Dermatologists Biologic Interventions Register (BADBIR)
March 2020 | Volume 19 | Issue 3 | Case Reports | 316 | Copyright © March 2020
Psoriasis is a chronic, systemic, inflammatory skin disease with a risk of comorbidities and a potential high impact on patients’ quality of life....
Read MorePityriasis Lichenoides Chronica in a Patient With Ankylosing Spondylitis Treated With Etanercept
March 2020 | Volume 19 | Issue 3 | Case Reports | 324 | Copyright © March 2020
Pityriasis lichenoides is a scarce cutaneous disorder with unknown etiology. It contains a range of clinical manifestations including acute papular lesions that quickly grow into pseudo vesicles and c...
Read MoreReal-World Clinical Experience With the IL-17 Receptor A Antagonist Brodalumab
February 2020 | Volume 19 | Issue 2 | Original Article | 132 | Copyright © February 2020
Psoriasis is a chronic, inflammatory, remitting/relapsing autoimmune dermatologic condition that manifests with scaly, erythematous plaques. It has a significantly negative effect on patient quality o...
Read MoreManagement of Residual Psoriasis in Patients on Biologic Treatment
February 2020 | Volume 19 | Issue 2 | Original Article | 188 | Copyright © February 2020
While biologics are highly effective, most psoriasis patients do not achieve...
Read MoreClinical and Molecular Effects of Interleukin-17 Pathway Blockade in Psoriasis
February 2020 | Volume 19 | Issue 2 | Original Article | 138 | Copyright © February 2020
The interleukin-17 (IL-17) pathway plays a crucial role in the development of psoriasis. Briefly, naive T cells differentiate into helper ...
Read MoreTreatment of Recalcitrant Acrodermatitis Continua of Hallopeau With Brodalumab
October 2019 | Volume 18 | Issue 10 | Editorials | 1047 | Copyright © October 2019
Acrodermatitis continua of Hallopeau (ACH) is a relatively rare chronic disorder with clinical findings of pustules and erythematous plaques on the digits.1 Although it is a variant of pustular psoria...
Read MoreThe Paradoxical Induction of Crohn’s Disease Following Treatment of Psoriatic Arthritis With Etanercept
August 2019 | Volume 18 | Issue 8 | Case Reports | 832 | Copyright © August 2019
Introduction: While psoriasis, psoriatic arthritis, and Crohn’s Disease (CD) all share a common central pathogenesis pathway and a wide overlap of treatment regime, discrepancie...
Read MorePrescribing Patterns Associated With Biologic Therapies for Psoriasis from a United States Medical Records Database
August 2019 | Volume 18 | Issue 8 | Original Article | 745 | Copyright © August 2019
Introduction: Selecting a systemic therapy for patients with psoriasis is a complex process, based on a variety of factors including psoriasis severity, comorbid health conditions, ac...
Read MoreCombination Use of Systemic Therapies in Psoriasis: Baseline Characteristics from the Corrona Psoriasis Registry
August 2019 | Volume 18 | Issue 8 | Original Article | 731 | Copyright © August 2019
Importance: There are increasing options for systemic combination therapy for psoriasis but a lack of literature around the characteristics of patients who are started on these regime...
Read MoreARTICLE: IL-23 Versus IL-17 in the Pathogenesis of Psoriasis: There Is More to the Story Than IL-17A
August 2019 | Volume 18 | Issue 8 | Supplement Individual Articles | 202 | Copyright © August 2019
Our understanding of psoriasis pathogenesis has evolved considerably. Cytokines within the TH1 and TH17 pathways have been found to be critical in psoriasis immunopathology. The TH17 pathway, which is...
Read MoreClinical Pathologic Mismatch in a TNF-α Inhibitor-Associated Drug Reaction
August 2019 | Volume 18 | Issue 8 | Case Reports | 218 | Copyright © August 2019
A 56-year-old Caucasian male with a history of chronic plaque psoriasis, primary sclerosing cholangitis status-post liver transplant on tacrolimus, and ulcerative colitis on infliximab developed a pro...
Read MoreSuccessful Treatment of Refractory Plaque-Type Psoriasis and Psoriatic Arthritis With Guselkumab and Adalimumab Combination Therapy: A Case Report
April 2019 | Volume 18 | Issue 4 | Case Reports | 394 | Copyright © April 2019
COPY: A number of biologics have been approved for use in plaque-type psoriasis. They act by either blocking the action of a specific type of cell or protein in the immune system.
CASE P...
Read MoreGrover’s Disease Treated With Total Skin Electron Beam Radiotherapy
April 2019 | Volume 18 | Issue 4 | Case Reports | 392 | Copyright © April 2019
Persistent Grover's disease can cause significant symptoms of pruritus thereby decreasing quality of life. Many patients undergo successful conservative management of their disease; however, a subset...
Read MoreTreatment of Psoriasis With Biologics and Apremilast in Patients With a History of Malignancy: A Retrospective Chart Review
April 2019 | Volume 18 | Issue 4 | Original Article | 387 | Copyright © April 2019
INTRODUCTION: Biologics have transformed the management of moderate-to-severe psoriasis. The risk of developing a malignancy during treatment is an important consideration, and many studies have b...
Read More